Compare Dollar Tree, Inc. (DLTR) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs Moderna, Inc. — how do they compare? Dollar Tree, Inc. trades at $128.75 (market cap $24.61B), while Moderna, Inc. trades at $63.66 (market cap $24.18B). The key difference: Dollar Tree, Inc. and Moderna, Inc. are close in size by market cap. Which is the better fit depends on your goals.
| DLTR | MRNA | |
|---|---|---|
Market Cap | $24.61B | $24.18B |
Sector | Health | Health |
52-Week High | $141.21 | $81.80 |
52-Week Low | $85.04 | $22.36 |
Enterprise Value | $31.20B | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $128.76, down 0.47% on the day. The stock exhibits a bullish technical trend, trading near its pivot point of $128 with support at $127. Fundamentally, the company reported a net loss of -$3.03B for 2025 despite strong operating cash flow of $2.86B. Recent news highlights a $2.5 billion share repurchase authorization announced on July 2, 2026 (Business Wire).
The outlook is mixed. Analyst consensus is a 'Buy' with a $126.69 price target, but significant risks exist from recent profitability challenges and competitive pressures. The share repurchase program may support EPS, but investors should weigh the negative net income against improving operational cash flow trends.
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
